Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.

Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM.

Am Heart J. 2009 Jun;157(6):1064-73. doi: 10.1016/j.ahj.2009.03.022.

PMID:
19464418
2.
3.

Guidelines for stroke prevention in patients with atrial fibrillation.

Howard PA.

Drugs. 1999 Dec;58(6):997-1009. Review.

PMID:
10651387
4.

A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation.

Abdelhafiz AH.

Clin Ther. 2001 Oct;23(10):1628-36. Review.

PMID:
11727726
5.

Pharmacoeconomics of atrial fibrillation and stroke prevention.

Bushnell CD, Matchar DB.

Am J Manag Care. 2004 Apr;10(3 Suppl):S66-71. Review.

6.
7.

The role of warfarin and aspirin in secondary prevention of stroke.

Elkind MS.

Curr Cardiol Rep. 2004 Mar;6(2):135-42. Review.

PMID:
14759359
8.

Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?

Miller PS, Andersson FL, Kalra L.

Stroke. 2005 Feb;36(2):360-6. Epub 2005 Jan 6. Review.

9.

Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.

von Schéele B, Fernandez M, Hogue SL, Kwong WJ.

Ann Pharmacother. 2013 May;47(5):671-85. doi: 10.1345/aph.1R411. Epub 2013 Apr 19. Review.

PMID:
23606551
10.

An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation.

Caro JJ.

Am J Manag Care. 2004 Dec;10(14 Suppl):S451-58; discussion S458-61. Review.

11.

Antiplatelet therapy for stroke prevention in atrial fibrillation.

Garg N, Kumar A, Flaker GC.

Mo Med. 2010 Jan-Feb;107(1):44-7. Review.

PMID:
20222295
12.

Atrial fibrillation and anticoagulation.

Garnier LF, Rouesnel P, Espitalier F.

Arch Mal Coeur Vaiss. 2004 Oct;97(10):1001-5. Review.

PMID:
16008178
13.

Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.

Albers GW; SPORTIF Investigators.

Am J Manag Care. 2004 Dec;10(14 Suppl):S462-9; discussion S469-73. Review.

14.

Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?

Hankey GJ.

Curr Opin Neurol. 2010 Feb;23(1):65-72. doi: 10.1097/WCO.0b013e328334e67b. Review.

PMID:
19949330
15.

Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.

Adcock AK, Lee-Iannotti JK, Aguilar MI, Hoffman-Snyder CR, Wingerchuk DM, Wellik KE, Demaerschalk BM.

Neurologist. 2012 Mar;18(2):102-7. doi: 10.1097/NRL.0b013e318247bcb6. Review.

PMID:
22367842
16.

Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal.

Odén A, Fahlén M, Hart RG.

Thromb Res. 2006;117(5):493-9. Epub 2004 Dec 25. Review.

PMID:
16517250
17.

Stroke prevention in atrial fibrillation--pharmacologic strategies.

Tiyyagura SR, Goldbarg SH, Mehta D.

Indian Heart J. 2007 Jul-Aug;59(4):311-5. Review.

PMID:
19126935
18.
19.

Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.

Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence.

Thromb Haemost. 2008 Feb;99(2):295-304. doi: 10.1160/TH07-08-0508. Review.

PMID:
18278178
20.

Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls.

Garwood CL, Corbett TL.

Ann Pharmacother. 2008 Apr;42(4):523-32. doi: 10.1345/aph.1K498. Epub 2008 Mar 11. Review.

PMID:
18334606
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk